nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—Salicylic acid—Niacin—atherosclerosis	0.308	1	CrCrCtD
Mesalazine—ALOX5—atherosclerosis	0.18	0.407	CbGaD
Mesalazine—MPO—atherosclerosis	0.116	0.262	CbGaD
Mesalazine—PPARG—atherosclerosis	0.103	0.233	CbGaD
Mesalazine—PTGS2—atherosclerosis	0.0436	0.0983	CbGaD
Mesalazine—MPO—superior mesenteric artery—atherosclerosis	0.014	0.289	CbGeAlD
Mesalazine—PPARG—leg—atherosclerosis	0.00242	0.0501	CbGeAlD
Mesalazine—PPARG—hindlimb—atherosclerosis	0.00216	0.0447	CbGeAlD
Mesalazine—PPARG—appendage—atherosclerosis	0.00186	0.0383	CbGeAlD
Mesalazine—MPO—artery—atherosclerosis	0.0015	0.0309	CbGeAlD
Mesalazine—PPARG—artery—atherosclerosis	0.00133	0.0274	CbGeAlD
Mesalazine—MPO—endothelium—atherosclerosis	0.00126	0.0261	CbGeAlD
Mesalazine—CHUK—connective tissue—atherosclerosis	0.00125	0.0259	CbGeAlD
Mesalazine—PTGS2—leg—atherosclerosis	0.00124	0.0256	CbGeAlD
Mesalazine—MPO—blood vessel—atherosclerosis	0.00116	0.0241	CbGeAlD
Mesalazine—PPARG—endothelium—atherosclerosis	0.00112	0.0231	CbGeAlD
Mesalazine—PTGS2—hindlimb—atherosclerosis	0.00111	0.0228	CbGeAlD
Mesalazine—CHUK—cardiovascular system—atherosclerosis	0.00109	0.0225	CbGeAlD
Mesalazine—PPARG—blood vessel—atherosclerosis	0.00103	0.0213	CbGeAlD
Mesalazine—CHUK—adipose tissue—atherosclerosis	0.000961	0.0199	CbGeAlD
Mesalazine—PTGS2—appendage—atherosclerosis	0.000949	0.0196	CbGeAlD
Mesalazine—IKBKB—connective tissue—atherosclerosis	0.000852	0.0176	CbGeAlD
Mesalazine—IKBKB—cardiovascular system—atherosclerosis	0.000741	0.0153	CbGeAlD
Mesalazine—PTGS1—artery—atherosclerosis	0.000709	0.0146	CbGeAlD
Mesalazine—ALOX5—connective tissue—atherosclerosis	0.000706	0.0146	CbGeAlD
Mesalazine—PTGS2—artery—atherosclerosis	0.000678	0.014	CbGeAlD
Mesalazine—CHUK—liver—atherosclerosis	0.000674	0.0139	CbGeAlD
Mesalazine—IKBKB—adipose tissue—atherosclerosis	0.000654	0.0135	CbGeAlD
Mesalazine—Olsalazine—IFNG—atherosclerosis	0.000641	0.209	CrCbGaD
Mesalazine—ALOX5—cardiovascular system—atherosclerosis	0.000614	0.0127	CbGeAlD
Mesalazine—PTGS1—endothelium—atherosclerosis	0.000599	0.0124	CbGeAlD
Mesalazine—MPO—connective tissue—atherosclerosis	0.000597	0.0123	CbGeAlD
Mesalazine—PTGS2—endothelium—atherosclerosis	0.000573	0.0118	CbGeAlD
Mesalazine—PTGS1—blood vessel—atherosclerosis	0.000553	0.0114	CbGeAlD
Mesalazine—ALOX5—adipose tissue—atherosclerosis	0.000542	0.0112	CbGeAlD
Mesalazine—PPARG—connective tissue—atherosclerosis	0.00053	0.0109	CbGeAlD
Mesalazine—PTGS2—blood vessel—atherosclerosis	0.000528	0.0109	CbGeAlD
Mesalazine—Olsalazine—ALOX5—atherosclerosis	0.000528	0.172	CrCbGaD
Mesalazine—MPO—cardiovascular system—atherosclerosis	0.00052	0.0107	CbGeAlD
Mesalazine—Aminosalicylic Acid—ALOX5—atherosclerosis	0.000496	0.162	CrCbGaD
Mesalazine—PPARG—cardiovascular system—atherosclerosis	0.000461	0.00952	CbGeAlD
Mesalazine—IKBKB—liver—atherosclerosis	0.000458	0.00946	CbGeAlD
Mesalazine—PPARG—adipose tissue—atherosclerosis	0.000407	0.0084	CbGeAlD
Mesalazine—ALOX5—liver—atherosclerosis	0.00038	0.00784	CbGeAlD
Mesalazine—MPO—liver—atherosclerosis	0.000321	0.00664	CbGeAlD
Mesalazine—Aminosalicylic Acid—MPO—atherosclerosis	0.00032	0.104	CrCbGaD
Mesalazine—Olsalazine—PPARG—atherosclerosis	0.000302	0.0983	CrCbGaD
Mesalazine—PPARG—liver—atherosclerosis	0.000285	0.00589	CbGeAlD
Mesalazine—PTGS1—connective tissue—atherosclerosis	0.000283	0.00585	CbGeAlD
Mesalazine—PTGS2—connective tissue—atherosclerosis	0.000271	0.00559	CbGeAlD
Mesalazine—PTGS1—cardiovascular system—atherosclerosis	0.000247	0.00509	CbGeAlD
Mesalazine—PTGS2—cardiovascular system—atherosclerosis	0.000236	0.00487	CbGeAlD
Mesalazine—PTGS1—adipose tissue—atherosclerosis	0.000217	0.00449	CbGeAlD
Mesalazine—PTGS2—adipose tissue—atherosclerosis	0.000208	0.00429	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—atherosclerosis	0.000186	0.0605	CrCbGaD
Mesalazine—PTGS2—liver—atherosclerosis	0.000146	0.00301	CbGeAlD
Mesalazine—Tinnitus—Pravastatin—atherosclerosis	0.000129	0.00128	CcSEcCtD
Mesalazine—Malaise—Lovastatin—atherosclerosis	0.000129	0.00127	CcSEcCtD
Mesalazine—Cardiac disorder—Pravastatin—atherosclerosis	0.000129	0.00127	CcSEcCtD
Mesalazine—Muscle spasms—Simvastatin—atherosclerosis	0.000128	0.00127	CcSEcCtD
Mesalazine—Vertigo—Lovastatin—atherosclerosis	0.000128	0.00127	CcSEcCtD
Mesalazine—Angioedema—Ezetimibe—atherosclerosis	0.000128	0.00126	CcSEcCtD
Mesalazine—Angiopathy—Niacin—atherosclerosis	0.000128	0.00126	CcSEcCtD
Mesalazine—Leukopenia—Lovastatin—atherosclerosis	0.000128	0.00126	CcSEcCtD
Mesalazine—Olsalazine—PTGS2—atherosclerosis	0.000128	0.0415	CrCbGaD
Mesalazine—Chills—Niacin—atherosclerosis	0.000126	0.00125	CcSEcCtD
Mesalazine—Malaise—Ezetimibe—atherosclerosis	0.000126	0.00125	CcSEcCtD
Mesalazine—Vision blurred—Simvastatin—atherosclerosis	0.000126	0.00124	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000125	0.00124	CcSEcCtD
Mesalazine—Tremor—Simvastatin—atherosclerosis	0.000125	0.00124	CcSEcCtD
Mesalazine—Alopecia—Niacin—atherosclerosis	0.000125	0.00123	CcSEcCtD
Mesalazine—Chills—Pravastatin—atherosclerosis	0.000124	0.00123	CcSEcCtD
Mesalazine—Insomnia—Rosuvastatin—atherosclerosis	0.000124	0.00123	CcSEcCtD
Mesalazine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000124	0.00122	CcSEcCtD
Mesalazine—Palpitations—Ezetimibe—atherosclerosis	0.000124	0.00122	CcSEcCtD
Mesalazine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000124	0.00122	CcSEcCtD
Mesalazine—Anaemia—Simvastatin—atherosclerosis	0.000123	0.00122	CcSEcCtD
Mesalazine—Erythema—Niacin—atherosclerosis	0.000123	0.00121	CcSEcCtD
Mesalazine—Alopecia—Pravastatin—atherosclerosis	0.000123	0.00121	CcSEcCtD
Mesalazine—Cough—Ezetimibe—atherosclerosis	0.000122	0.00121	CcSEcCtD
Mesalazine—Angioedema—Simvastatin—atherosclerosis	0.000122	0.00121	CcSEcCtD
Mesalazine—Myalgia—Lovastatin—atherosclerosis	0.000122	0.0012	CcSEcCtD
Mesalazine—Arthralgia—Lovastatin—atherosclerosis	0.000122	0.0012	CcSEcCtD
Mesalazine—Chest pain—Lovastatin—atherosclerosis	0.000122	0.0012	CcSEcCtD
Mesalazine—Anxiety—Lovastatin—atherosclerosis	0.000121	0.0012	CcSEcCtD
Mesalazine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000121	0.0012	CcSEcCtD
Mesalazine—Hypertension—Ezetimibe—atherosclerosis	0.000121	0.0012	CcSEcCtD
Mesalazine—Flatulence—Niacin—atherosclerosis	0.000121	0.00119	CcSEcCtD
Mesalazine—Malaise—Simvastatin—atherosclerosis	0.00012	0.00119	CcSEcCtD
Mesalazine—Tension—Niacin—atherosclerosis	0.00012	0.00119	CcSEcCtD
Mesalazine—Discomfort—Lovastatin—atherosclerosis	0.00012	0.00119	CcSEcCtD
Mesalazine—Vertigo—Simvastatin—atherosclerosis	0.00012	0.00119	CcSEcCtD
Mesalazine—Diflunisal—PTGS2—atherosclerosis	0.00012	0.039	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—atherosclerosis	0.00012	0.039	CrCbGaD
Mesalazine—Leukopenia—Simvastatin—atherosclerosis	0.00012	0.00118	CcSEcCtD
Mesalazine—Chest pain—Ezetimibe—atherosclerosis	0.000119	0.00118	CcSEcCtD
Mesalazine—Arthralgia—Ezetimibe—atherosclerosis	0.000119	0.00118	CcSEcCtD
Mesalazine—Myalgia—Ezetimibe—atherosclerosis	0.000119	0.00118	CcSEcCtD
Mesalazine—Nervousness—Niacin—atherosclerosis	0.000119	0.00118	CcSEcCtD
Mesalazine—Flatulence—Pravastatin—atherosclerosis	0.000119	0.00118	CcSEcCtD
Mesalazine—Dry mouth—Lovastatin—atherosclerosis	0.000119	0.00118	CcSEcCtD
Mesalazine—Tension—Pravastatin—atherosclerosis	0.000119	0.00117	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000118	0.00117	CcSEcCtD
Mesalazine—Dysgeusia—Pravastatin—atherosclerosis	0.000118	0.00117	CcSEcCtD
Mesalazine—Muscle spasms—Niacin—atherosclerosis	0.000118	0.00117	CcSEcCtD
Mesalazine—Discomfort—Ezetimibe—atherosclerosis	0.000118	0.00116	CcSEcCtD
Mesalazine—Pain—Rosuvastatin—atherosclerosis	0.000118	0.00116	CcSEcCtD
Mesalazine—Constipation—Rosuvastatin—atherosclerosis	0.000118	0.00116	CcSEcCtD
Mesalazine—Confusional state—Lovastatin—atherosclerosis	0.000118	0.00116	CcSEcCtD
Mesalazine—Nervousness—Pravastatin—atherosclerosis	0.000117	0.00116	CcSEcCtD
Mesalazine—Dry mouth—Ezetimibe—atherosclerosis	0.000117	0.00115	CcSEcCtD
Mesalazine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000117	0.00115	CcSEcCtD
Mesalazine—Muscle spasms—Pravastatin—atherosclerosis	0.000116	0.00115	CcSEcCtD
Mesalazine—Infection—Lovastatin—atherosclerosis	0.000116	0.00114	CcSEcCtD
Mesalazine—Vision blurred—Niacin—atherosclerosis	0.000116	0.00114	CcSEcCtD
Mesalazine—Confusional state—Ezetimibe—atherosclerosis	0.000115	0.00114	CcSEcCtD
Mesalazine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000114	0.00113	CcSEcCtD
Mesalazine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000114	0.00113	CcSEcCtD
Mesalazine—Vision blurred—Pravastatin—atherosclerosis	0.000114	0.00112	CcSEcCtD
Mesalazine—Myalgia—Simvastatin—atherosclerosis	0.000114	0.00112	CcSEcCtD
Mesalazine—Chest pain—Simvastatin—atherosclerosis	0.000114	0.00112	CcSEcCtD
Mesalazine—Arthralgia—Simvastatin—atherosclerosis	0.000114	0.00112	CcSEcCtD
Mesalazine—Infection—Ezetimibe—atherosclerosis	0.000114	0.00112	CcSEcCtD
Mesalazine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000113	0.00112	CcSEcCtD
Mesalazine—Anxiety—Simvastatin—atherosclerosis	0.000113	0.00112	CcSEcCtD
Mesalazine—Tremor—Pravastatin—atherosclerosis	0.000113	0.00112	CcSEcCtD
Mesalazine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000112	0.00111	CcSEcCtD
Mesalazine—Discomfort—Simvastatin—atherosclerosis	0.000112	0.00111	CcSEcCtD
Mesalazine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000112	0.00111	CcSEcCtD
Mesalazine—Angioedema—Niacin—atherosclerosis	0.000112	0.00111	CcSEcCtD
Mesalazine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000112	0.00111	CcSEcCtD
Mesalazine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000112	0.00111	CcSEcCtD
Mesalazine—Anaemia—Pravastatin—atherosclerosis	0.000112	0.0011	CcSEcCtD
Mesalazine—Anorexia—Lovastatin—atherosclerosis	0.000111	0.0011	CcSEcCtD
Mesalazine—Skin disorder—Ezetimibe—atherosclerosis	0.000111	0.0011	CcSEcCtD
Mesalazine—Angioedema—Pravastatin—atherosclerosis	0.00011	0.00109	CcSEcCtD
Mesalazine—Vertigo—Niacin—atherosclerosis	0.00011	0.00109	CcSEcCtD
Mesalazine—Syncope—Niacin—atherosclerosis	0.00011	0.00109	CcSEcCtD
Mesalazine—Confusional state—Simvastatin—atherosclerosis	0.00011	0.00109	CcSEcCtD
Mesalazine—Leukopenia—Niacin—atherosclerosis	0.00011	0.00109	CcSEcCtD
Mesalazine—Urticaria—Rosuvastatin—atherosclerosis	0.000109	0.00108	CcSEcCtD
Mesalazine—Oedema—Simvastatin—atherosclerosis	0.000109	0.00108	CcSEcCtD
Mesalazine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000109	0.00108	CcSEcCtD
Mesalazine—Malaise—Pravastatin—atherosclerosis	0.000109	0.00108	CcSEcCtD
Mesalazine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000109	0.00107	CcSEcCtD
Mesalazine—Vertigo—Pravastatin—atherosclerosis	0.000109	0.00107	CcSEcCtD
Mesalazine—Palpitations—Niacin—atherosclerosis	0.000108	0.00107	CcSEcCtD
Mesalazine—Infection—Simvastatin—atherosclerosis	0.000108	0.00107	CcSEcCtD
Mesalazine—Leukopenia—Pravastatin—atherosclerosis	0.000108	0.00107	CcSEcCtD
Mesalazine—Loss of consciousness—Niacin—atherosclerosis	0.000108	0.00107	CcSEcCtD
Mesalazine—Cough—Niacin—atherosclerosis	0.000107	0.00106	CcSEcCtD
Mesalazine—Diflunisal—ALB—atherosclerosis	0.000107	0.0348	CrCbGaD
Mesalazine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000107	0.00105	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000106	0.00105	CcSEcCtD
Mesalazine—Insomnia—Lovastatin—atherosclerosis	0.000105	0.00104	CcSEcCtD
Mesalazine—Cough—Pravastatin—atherosclerosis	0.000105	0.00104	CcSEcCtD
Mesalazine—Paraesthesia—Lovastatin—atherosclerosis	0.000105	0.00103	CcSEcCtD
Mesalazine—Myalgia—Niacin—atherosclerosis	0.000104	0.00103	CcSEcCtD
Mesalazine—Arthralgia—Niacin—atherosclerosis	0.000104	0.00103	CcSEcCtD
Mesalazine—Hypertension—Pravastatin—atherosclerosis	0.000104	0.00103	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000104	0.00103	CcSEcCtD
Mesalazine—Anorexia—Simvastatin—atherosclerosis	0.000104	0.00103	CcSEcCtD
Mesalazine—Dyspnoea—Lovastatin—atherosclerosis	0.000104	0.00103	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000104	0.00102	CcSEcCtD
Mesalazine—Insomnia—Ezetimibe—atherosclerosis	0.000103	0.00102	CcSEcCtD
Mesalazine—Arthralgia—Pravastatin—atherosclerosis	0.000103	0.00102	CcSEcCtD
Mesalazine—Chest pain—Pravastatin—atherosclerosis	0.000103	0.00102	CcSEcCtD
Mesalazine—Myalgia—Pravastatin—atherosclerosis	0.000103	0.00102	CcSEcCtD
Mesalazine—Paraesthesia—Ezetimibe—atherosclerosis	0.000103	0.00101	CcSEcCtD
Mesalazine—Dyspepsia—Lovastatin—atherosclerosis	0.000103	0.00101	CcSEcCtD
Mesalazine—Anxiety—Pravastatin—atherosclerosis	0.000102	0.00101	CcSEcCtD
Mesalazine—Dry mouth—Niacin—atherosclerosis	0.000102	0.00101	CcSEcCtD
Mesalazine—Dyspnoea—Ezetimibe—atherosclerosis	0.000102	0.00101	CcSEcCtD
Mesalazine—Discomfort—Pravastatin—atherosclerosis	0.000102	0.001	CcSEcCtD
Mesalazine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000101	0.001	CcSEcCtD
Mesalazine—Decreased appetite—Lovastatin—atherosclerosis	0.000101	0.001	CcSEcCtD
Mesalazine—Dyspepsia—Ezetimibe—atherosclerosis	0.000101	0.000995	CcSEcCtD
Mesalazine—Fatigue—Lovastatin—atherosclerosis	0.000101	0.000993	CcSEcCtD
Mesalazine—Oedema—Niacin—atherosclerosis	0.0001	0.000989	CcSEcCtD
Mesalazine—Anaphylactic shock—Niacin—atherosclerosis	0.0001	0.000989	CcSEcCtD
Mesalazine—Pain—Lovastatin—atherosclerosis	9.97e-05	0.000985	CcSEcCtD
Mesalazine—Constipation—Lovastatin—atherosclerosis	9.97e-05	0.000985	CcSEcCtD
Mesalazine—Confusional state—Pravastatin—atherosclerosis	9.94e-05	0.000982	CcSEcCtD
Mesalazine—Decreased appetite—Ezetimibe—atherosclerosis	9.94e-05	0.000982	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	9.93e-05	0.000982	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	9.87e-05	0.000975	CcSEcCtD
Mesalazine—Asthenia—Rosuvastatin—atherosclerosis	9.87e-05	0.000975	CcSEcCtD
Mesalazine—Insomnia—Simvastatin—atherosclerosis	9.86e-05	0.000975	CcSEcCtD
Mesalazine—Anaphylactic shock—Pravastatin—atherosclerosis	9.86e-05	0.000974	CcSEcCtD
Mesalazine—Oedema—Pravastatin—atherosclerosis	9.86e-05	0.000974	CcSEcCtD
Mesalazine—Fatigue—Ezetimibe—atherosclerosis	9.86e-05	0.000974	CcSEcCtD
Mesalazine—Shock—Niacin—atherosclerosis	9.85e-05	0.000973	CcSEcCtD
Mesalazine—Infection—Pravastatin—atherosclerosis	9.79e-05	0.000968	CcSEcCtD
Mesalazine—Paraesthesia—Simvastatin—atherosclerosis	9.79e-05	0.000967	CcSEcCtD
Mesalazine—Pain—Ezetimibe—atherosclerosis	9.78e-05	0.000966	CcSEcCtD
Mesalazine—Constipation—Ezetimibe—atherosclerosis	9.78e-05	0.000966	CcSEcCtD
Mesalazine—Tachycardia—Niacin—atherosclerosis	9.77e-05	0.000966	CcSEcCtD
Mesalazine—Pruritus—Rosuvastatin—atherosclerosis	9.73e-05	0.000962	CcSEcCtD
Mesalazine—Skin disorder—Niacin—atherosclerosis	9.72e-05	0.000961	CcSEcCtD
Mesalazine—Dyspnoea—Simvastatin—atherosclerosis	9.72e-05	0.000961	CcSEcCtD
Mesalazine—Hyperhidrosis—Niacin—atherosclerosis	9.68e-05	0.000956	CcSEcCtD
Mesalazine—Thrombocytopenia—Pravastatin—atherosclerosis	9.65e-05	0.000954	CcSEcCtD
Mesalazine—Feeling abnormal—Lovastatin—atherosclerosis	9.61e-05	0.000949	CcSEcCtD
Mesalazine—Dyspepsia—Simvastatin—atherosclerosis	9.6e-05	0.000948	CcSEcCtD
Mesalazine—Anorexia—Niacin—atherosclerosis	9.54e-05	0.000943	CcSEcCtD
Mesalazine—Gastrointestinal pain—Lovastatin—atherosclerosis	9.53e-05	0.000942	CcSEcCtD
Mesalazine—Hyperhidrosis—Pravastatin—atherosclerosis	9.53e-05	0.000942	CcSEcCtD
Mesalazine—Decreased appetite—Simvastatin—atherosclerosis	9.48e-05	0.000937	CcSEcCtD
Mesalazine—Feeling abnormal—Ezetimibe—atherosclerosis	9.42e-05	0.000931	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Simvastatin—atherosclerosis	9.41e-05	0.00093	CcSEcCtD
Mesalazine—Diarrhoea—Rosuvastatin—atherosclerosis	9.41e-05	0.00093	CcSEcCtD
Mesalazine—Fatigue—Simvastatin—atherosclerosis	9.4e-05	0.000929	CcSEcCtD
Mesalazine—Anorexia—Pravastatin—atherosclerosis	9.4e-05	0.000929	CcSEcCtD
Mesalazine—Hypotension—Niacin—atherosclerosis	9.36e-05	0.000924	CcSEcCtD
Mesalazine—Gastrointestinal pain—Ezetimibe—atherosclerosis	9.35e-05	0.000924	CcSEcCtD
Mesalazine—Pain—Simvastatin—atherosclerosis	9.32e-05	0.000921	CcSEcCtD
Mesalazine—Constipation—Simvastatin—atherosclerosis	9.32e-05	0.000921	CcSEcCtD
Mesalazine—Urticaria—Lovastatin—atherosclerosis	9.26e-05	0.000915	CcSEcCtD
Mesalazine—Abdominal pain—Lovastatin—atherosclerosis	9.22e-05	0.000911	CcSEcCtD
Mesalazine—Body temperature increased—Lovastatin—atherosclerosis	9.22e-05	0.000911	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Niacin—atherosclerosis	9.12e-05	0.000901	CcSEcCtD
Mesalazine—Dizziness—Rosuvastatin—atherosclerosis	9.1e-05	0.000899	CcSEcCtD
Mesalazine—Urticaria—Ezetimibe—atherosclerosis	9.08e-05	0.000898	CcSEcCtD
Mesalazine—Insomnia—Niacin—atherosclerosis	9.06e-05	0.000895	CcSEcCtD
Mesalazine—Abdominal pain—Ezetimibe—atherosclerosis	9.04e-05	0.000893	CcSEcCtD
Mesalazine—Body temperature increased—Ezetimibe—atherosclerosis	9.04e-05	0.000893	CcSEcCtD
Mesalazine—Paraesthesia—Niacin—atherosclerosis	8.99e-05	0.000888	CcSEcCtD
Mesalazine—Feeling abnormal—Simvastatin—atherosclerosis	8.99e-05	0.000888	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	8.98e-05	0.000887	CcSEcCtD
Mesalazine—Dyspnoea—Niacin—atherosclerosis	8.93e-05	0.000882	CcSEcCtD
Mesalazine—Gastrointestinal pain—Simvastatin—atherosclerosis	8.92e-05	0.000881	CcSEcCtD
Mesalazine—Insomnia—Pravastatin—atherosclerosis	8.92e-05	0.000881	CcSEcCtD
Mesalazine—Somnolence—Niacin—atherosclerosis	8.9e-05	0.00088	CcSEcCtD
Mesalazine—Paraesthesia—Pravastatin—atherosclerosis	8.85e-05	0.000875	CcSEcCtD
Mesalazine—Dyspepsia—Niacin—atherosclerosis	8.81e-05	0.000871	CcSEcCtD
Mesalazine—Dyspnoea—Pravastatin—atherosclerosis	8.79e-05	0.000868	CcSEcCtD
Mesalazine—Decreased appetite—Niacin—atherosclerosis	8.7e-05	0.00086	CcSEcCtD
Mesalazine—Dyspepsia—Pravastatin—atherosclerosis	8.68e-05	0.000857	CcSEcCtD
Mesalazine—Rash—Rosuvastatin—atherosclerosis	8.67e-05	0.000857	CcSEcCtD
Mesalazine—Dermatitis—Rosuvastatin—atherosclerosis	8.66e-05	0.000856	CcSEcCtD
Mesalazine—Urticaria—Simvastatin—atherosclerosis	8.66e-05	0.000856	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Niacin—atherosclerosis	8.64e-05	0.000854	CcSEcCtD
Mesalazine—Abdominal pain—Simvastatin—atherosclerosis	8.62e-05	0.000852	CcSEcCtD
Mesalazine—Body temperature increased—Simvastatin—atherosclerosis	8.62e-05	0.000852	CcSEcCtD
Mesalazine—Headache—Rosuvastatin—atherosclerosis	8.62e-05	0.000852	CcSEcCtD
Mesalazine—Hypersensitivity—Lovastatin—atherosclerosis	8.59e-05	0.000849	CcSEcCtD
Mesalazine—Decreased appetite—Pravastatin—atherosclerosis	8.57e-05	0.000847	CcSEcCtD
Mesalazine—Pain—Niacin—atherosclerosis	8.56e-05	0.000846	CcSEcCtD
Mesalazine—Fatigue—Pravastatin—atherosclerosis	8.5e-05	0.00084	CcSEcCtD
Mesalazine—Constipation—Pravastatin—atherosclerosis	8.43e-05	0.000833	CcSEcCtD
Mesalazine—Pain—Pravastatin—atherosclerosis	8.43e-05	0.000833	CcSEcCtD
Mesalazine—Hypersensitivity—Ezetimibe—atherosclerosis	8.42e-05	0.000832	CcSEcCtD
Mesalazine—Asthenia—Lovastatin—atherosclerosis	8.36e-05	0.000826	CcSEcCtD
Mesalazine—Pruritus—Lovastatin—atherosclerosis	8.25e-05	0.000815	CcSEcCtD
Mesalazine—Asthenia—Ezetimibe—atherosclerosis	8.2e-05	0.000811	CcSEcCtD
Mesalazine—Gastrointestinal pain—Niacin—atherosclerosis	8.19e-05	0.000809	CcSEcCtD
Mesalazine—Nausea—Rosuvastatin—atherosclerosis	8.17e-05	0.000807	CcSEcCtD
Mesalazine—Feeling abnormal—Pravastatin—atherosclerosis	8.12e-05	0.000803	CcSEcCtD
Mesalazine—Pruritus—Ezetimibe—atherosclerosis	8.09e-05	0.000799	CcSEcCtD
Mesalazine—Gastrointestinal pain—Pravastatin—atherosclerosis	8.06e-05	0.000797	CcSEcCtD
Mesalazine—Hypersensitivity—Simvastatin—atherosclerosis	8.03e-05	0.000794	CcSEcCtD
Mesalazine—Diarrhoea—Lovastatin—atherosclerosis	7.98e-05	0.000788	CcSEcCtD
Mesalazine—Urticaria—Niacin—atherosclerosis	7.95e-05	0.000786	CcSEcCtD
Mesalazine—Abdominal pain—Niacin—atherosclerosis	7.91e-05	0.000782	CcSEcCtD
Mesalazine—Body temperature increased—Niacin—atherosclerosis	7.91e-05	0.000782	CcSEcCtD
Mesalazine—Urticaria—Pravastatin—atherosclerosis	7.83e-05	0.000774	CcSEcCtD
Mesalazine—Asthenia—Simvastatin—atherosclerosis	7.82e-05	0.000773	CcSEcCtD
Mesalazine—Diarrhoea—Ezetimibe—atherosclerosis	7.82e-05	0.000773	CcSEcCtD
Mesalazine—Body temperature increased—Pravastatin—atherosclerosis	7.79e-05	0.00077	CcSEcCtD
Mesalazine—Abdominal pain—Pravastatin—atherosclerosis	7.79e-05	0.00077	CcSEcCtD
Mesalazine—Pruritus—Simvastatin—atherosclerosis	7.71e-05	0.000762	CcSEcCtD
Mesalazine—Dizziness—Lovastatin—atherosclerosis	7.71e-05	0.000762	CcSEcCtD
Mesalazine—Dizziness—Ezetimibe—atherosclerosis	7.56e-05	0.000747	CcSEcCtD
Mesalazine—Diarrhoea—Simvastatin—atherosclerosis	7.46e-05	0.000737	CcSEcCtD
Mesalazine—Vomiting—Lovastatin—atherosclerosis	7.41e-05	0.000732	CcSEcCtD
Mesalazine—Hypersensitivity—Niacin—atherosclerosis	7.38e-05	0.000729	CcSEcCtD
Mesalazine—Rash—Lovastatin—atherosclerosis	7.35e-05	0.000726	CcSEcCtD
Mesalazine—Dermatitis—Lovastatin—atherosclerosis	7.34e-05	0.000726	CcSEcCtD
Mesalazine—Headache—Lovastatin—atherosclerosis	7.3e-05	0.000722	CcSEcCtD
Mesalazine—Vomiting—Ezetimibe—atherosclerosis	7.27e-05	0.000718	CcSEcCtD
Mesalazine—Hypersensitivity—Pravastatin—atherosclerosis	7.26e-05	0.000718	CcSEcCtD
Mesalazine—Dizziness—Simvastatin—atherosclerosis	7.21e-05	0.000712	CcSEcCtD
Mesalazine—Rash—Ezetimibe—atherosclerosis	7.21e-05	0.000712	CcSEcCtD
Mesalazine—Dermatitis—Ezetimibe—atherosclerosis	7.2e-05	0.000712	CcSEcCtD
Mesalazine—Asthenia—Niacin—atherosclerosis	7.18e-05	0.00071	CcSEcCtD
Mesalazine—Headache—Ezetimibe—atherosclerosis	7.16e-05	0.000708	CcSEcCtD
Mesalazine—Pruritus—Niacin—atherosclerosis	7.08e-05	0.0007	CcSEcCtD
Mesalazine—Asthenia—Pravastatin—atherosclerosis	7.07e-05	0.000699	CcSEcCtD
Mesalazine—Pruritus—Pravastatin—atherosclerosis	6.97e-05	0.000689	CcSEcCtD
Mesalazine—Vomiting—Simvastatin—atherosclerosis	6.93e-05	0.000685	CcSEcCtD
Mesalazine—Nausea—Lovastatin—atherosclerosis	6.92e-05	0.000684	CcSEcCtD
Mesalazine—Rash—Simvastatin—atherosclerosis	6.87e-05	0.000679	CcSEcCtD
Mesalazine—Dermatitis—Simvastatin—atherosclerosis	6.87e-05	0.000679	CcSEcCtD
Mesalazine—Diarrhoea—Niacin—atherosclerosis	6.85e-05	0.000677	CcSEcCtD
Mesalazine—Headache—Simvastatin—atherosclerosis	6.83e-05	0.000675	CcSEcCtD
Mesalazine—Nausea—Ezetimibe—atherosclerosis	6.79e-05	0.000671	CcSEcCtD
Mesalazine—Diarrhoea—Pravastatin—atherosclerosis	6.74e-05	0.000666	CcSEcCtD
Mesalazine—Salicylic acid—PTGS2—atherosclerosis	6.67e-05	0.0217	CrCbGaD
Mesalazine—Dizziness—Niacin—atherosclerosis	6.62e-05	0.000654	CcSEcCtD
Mesalazine—Dizziness—Pravastatin—atherosclerosis	6.52e-05	0.000644	CcSEcCtD
Mesalazine—Nausea—Simvastatin—atherosclerosis	6.48e-05	0.00064	CcSEcCtD
Mesalazine—Vomiting—Niacin—atherosclerosis	6.37e-05	0.000629	CcSEcCtD
Mesalazine—Rash—Niacin—atherosclerosis	6.31e-05	0.000624	CcSEcCtD
Mesalazine—Dermatitis—Niacin—atherosclerosis	6.31e-05	0.000623	CcSEcCtD
Mesalazine—Headache—Niacin—atherosclerosis	6.27e-05	0.00062	CcSEcCtD
Mesalazine—Vomiting—Pravastatin—atherosclerosis	6.27e-05	0.000619	CcSEcCtD
Mesalazine—Rash—Pravastatin—atherosclerosis	6.22e-05	0.000614	CcSEcCtD
Mesalazine—Dermatitis—Pravastatin—atherosclerosis	6.21e-05	0.000614	CcSEcCtD
Mesalazine—Headache—Pravastatin—atherosclerosis	6.18e-05	0.00061	CcSEcCtD
Mesalazine—Nausea—Niacin—atherosclerosis	5.95e-05	0.000588	CcSEcCtD
Mesalazine—Salicylic acid—ALB—atherosclerosis	5.94e-05	0.0193	CrCbGaD
Mesalazine—Nausea—Pravastatin—atherosclerosis	5.86e-05	0.000579	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—NCF1—atherosclerosis	6.75e-06	7.06e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MAPK3—atherosclerosis	6.74e-06	7.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LDLR—atherosclerosis	6.74e-06	7.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PRKCG—atherosclerosis	6.71e-06	7.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	6.7e-06	7e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PDGFB—atherosclerosis	6.67e-06	6.97e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—ALB—atherosclerosis	6.65e-06	6.95e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SCARB1—atherosclerosis	6.65e-06	6.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PLA2G1B—atherosclerosis	6.63e-06	6.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—AKT1—atherosclerosis	6.61e-06	6.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL6—atherosclerosis	6.61e-06	6.91e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOB—atherosclerosis	6.56e-06	6.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	6.56e-06	6.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD36—atherosclerosis	6.56e-06	6.86e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TGFB1—atherosclerosis	6.54e-06	6.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CRP—atherosclerosis	6.52e-06	6.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NFKB1—atherosclerosis	6.51e-06	6.81e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HSPA1B—atherosclerosis	6.51e-06	6.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	6.5e-06	6.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—IL6—atherosclerosis	6.5e-06	6.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	6.48e-06	6.78e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.47e-06	6.77e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ESR1—atherosclerosis	6.45e-06	6.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALOX5—atherosclerosis	6.41e-06	6.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK8—atherosclerosis	6.4e-06	6.69e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTM1—atherosclerosis	6.39e-06	6.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EDNRA—atherosclerosis	6.38e-06	6.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCR2—atherosclerosis	6.38e-06	6.67e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—NOS3—atherosclerosis	6.36e-06	6.65e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CYBA—atherosclerosis	6.35e-06	6.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTHFR—atherosclerosis	6.33e-06	6.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NCF1—atherosclerosis	6.3e-06	6.59e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMGCR—atherosclerosis	6.28e-06	6.56e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—LPL—atherosclerosis	6.27e-06	6.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NFKB1—atherosclerosis	6.25e-06	6.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TLR4—atherosclerosis	6.25e-06	6.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PLAT—atherosclerosis	6.22e-06	6.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GHRL—atherosclerosis	6.22e-06	6.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PARP1—atherosclerosis	6.22e-06	6.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PDGFB—atherosclerosis	6.16e-06	6.44e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GPX1—atherosclerosis	6.11e-06	6.39e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—atherosclerosis	6.11e-06	6.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PDGFB—atherosclerosis	6.05e-06	6.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KNG1—atherosclerosis	6.02e-06	6.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—AKT1—atherosclerosis	6e-06	6.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ICAM1—atherosclerosis	5.99e-06	6.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGTR1—atherosclerosis	5.98e-06	6.25e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CD36—atherosclerosis	5.95e-06	6.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CYBA—atherosclerosis	5.92e-06	6.19e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	5.92e-06	6.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CRP—atherosclerosis	5.91e-06	6.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NFKB1—atherosclerosis	5.91e-06	6.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOE—atherosclerosis	5.89e-06	6.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CAV1—atherosclerosis	5.83e-06	6.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PLG—atherosclerosis	5.83e-06	6.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOA1—atherosclerosis	5.82e-06	6.09e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—atherosclerosis	5.82e-06	6.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK8—atherosclerosis	5.8e-06	6.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PARP1—atherosclerosis	5.8e-06	6.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NAMPT—atherosclerosis	5.75e-06	6.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	5.71e-06	5.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—LIPC—atherosclerosis	5.71e-06	5.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOC3—atherosclerosis	5.68e-06	5.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NFKB1—atherosclerosis	5.67e-06	5.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TLR4—atherosclerosis	5.67e-06	5.92e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.66e-06	5.92e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—atherosclerosis	5.64e-06	5.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—LDLR—atherosclerosis	5.64e-06	5.9e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ABCA1—atherosclerosis	5.6e-06	5.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK3—atherosclerosis	5.59e-06	5.85e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PPARA—atherosclerosis	5.54e-06	5.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SOCS3—atherosclerosis	5.52e-06	5.77e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CETP—atherosclerosis	5.51e-06	5.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS2—atherosclerosis	5.49e-06	5.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KNG1—atherosclerosis	5.46e-06	5.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ICAM1—atherosclerosis	5.43e-06	5.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGTR1—atherosclerosis	5.42e-06	5.67e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—atherosclerosis	5.41e-06	5.66e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AGT—atherosclerosis	5.36e-06	5.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP3—atherosclerosis	5.33e-06	5.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF2—atherosclerosis	5.31e-06	5.55e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SERPINE1—atherosclerosis	5.3e-06	5.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PLG—atherosclerosis	5.29e-06	5.53e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SCARB1—atherosclerosis	5.28e-06	5.52e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOE—atherosclerosis	5.25e-06	5.49e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CAV1—atherosclerosis	5.21e-06	5.44e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOA1—atherosclerosis	5.19e-06	5.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOB—atherosclerosis	5.15e-06	5.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	5.14e-06	5.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EDN1—atherosclerosis	5.07e-06	5.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK3—atherosclerosis	5.07e-06	5.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL5—atherosclerosis	5.03e-06	5.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—INS—atherosclerosis	5.03e-06	5.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SOCS3—atherosclerosis	5.01e-06	5.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMGCR—atherosclerosis	4.98e-06	5.21e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—atherosclerosis	4.93e-06	5.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LPL—atherosclerosis	4.92e-06	5.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP3—atherosclerosis	4.83e-06	5.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF2—atherosclerosis	4.81e-06	5.03e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMOX1—atherosclerosis	4.8e-06	5.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRKCG—atherosclerosis	4.78e-06	5e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CG—atherosclerosis	4.74e-06	4.96e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOB—atherosclerosis	4.67e-06	4.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SPP1—atherosclerosis	4.66e-06	4.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SERPINE1—atherosclerosis	4.62e-06	4.83e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOB—atherosclerosis	4.6e-06	4.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EDN1—atherosclerosis	4.6e-06	4.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL5—atherosclerosis	4.56e-06	4.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNG—atherosclerosis	4.56e-06	4.77e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—atherosclerosis	4.55e-06	4.76e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—INS—atherosclerosis	4.49e-06	4.69e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—atherosclerosis	4.47e-06	4.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LPL—atherosclerosis	4.46e-06	4.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCA1—atherosclerosis	4.44e-06	4.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS3—atherosclerosis	4.41e-06	4.61e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—LPL—atherosclerosis	4.39e-06	4.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOB—atherosclerosis	4.36e-06	4.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKCG—atherosclerosis	4.34e-06	4.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PDGFB—atherosclerosis	4.31e-06	4.51e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—atherosclerosis	4.28e-06	4.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SPP1—atherosclerosis	4.23e-06	4.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGT—atherosclerosis	4.21e-06	4.4e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CD36—atherosclerosis	4.17e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LPL—atherosclerosis	4.16e-06	4.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—atherosclerosis	4.13e-06	4.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—atherosclerosis	4.12e-06	4.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LEP—atherosclerosis	4.12e-06	4.31e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—atherosclerosis	4.11e-06	4.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—atherosclerosis	4.09e-06	4.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CAV1—atherosclerosis	4.09e-06	4.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOA1—atherosclerosis	4.08e-06	4.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—atherosclerosis	4.07e-06	4.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PRKCG—atherosclerosis	4.05e-06	4.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—atherosclerosis	4.04e-06	4.22e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—atherosclerosis	3.95e-06	4.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—atherosclerosis	3.94e-06	4.12e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—atherosclerosis	3.94e-06	4.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFB—atherosclerosis	3.91e-06	4.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—F2—atherosclerosis	3.89e-06	4.07e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARA—atherosclerosis	3.88e-06	4.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGT—atherosclerosis	3.82e-06	3.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMOX1—atherosclerosis	3.81e-06	3.98e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NFKB1—atherosclerosis	3.79e-06	3.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—atherosclerosis	3.77e-06	3.94e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AGT—atherosclerosis	3.76e-06	3.93e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—atherosclerosis	3.75e-06	3.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—atherosclerosis	3.74e-06	3.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—atherosclerosis	3.74e-06	3.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK8—atherosclerosis	3.73e-06	3.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—atherosclerosis	3.72e-06	3.89e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—atherosclerosis	3.71e-06	3.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CAV1—atherosclerosis	3.71e-06	3.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOA1—atherosclerosis	3.7e-06	3.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—atherosclerosis	3.69e-06	3.86e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—atherosclerosis	3.68e-06	3.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOB—atherosclerosis	3.65e-06	3.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFB—atherosclerosis	3.65e-06	3.81e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAV1—atherosclerosis	3.65e-06	3.81e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOA1—atherosclerosis	3.64e-06	3.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—atherosclerosis	3.62e-06	3.79e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—atherosclerosis	3.6e-06	3.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—atherosclerosis	3.57e-06	3.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—atherosclerosis	3.55e-06	3.71e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—F2—atherosclerosis	3.53e-06	3.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—INS—atherosclerosis	3.52e-06	3.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—atherosclerosis	3.49e-06	3.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—LPL—atherosclerosis	3.49e-06	3.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—atherosclerosis	3.47e-06	3.62e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CAV1—atherosclerosis	3.46e-06	3.61e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—atherosclerosis	3.45e-06	3.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOA1—atherosclerosis	3.45e-06	3.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFKB1—atherosclerosis	3.44e-06	3.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—atherosclerosis	3.42e-06	3.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—atherosclerosis	3.41e-06	3.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—atherosclerosis	3.41e-06	3.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—atherosclerosis	3.4e-06	3.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK8—atherosclerosis	3.38e-06	3.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—atherosclerosis	3.37e-06	3.53e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—atherosclerosis	3.32e-06	3.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CD36—atherosclerosis	3.31e-06	3.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—atherosclerosis	3.28e-06	3.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—atherosclerosis	3.26e-06	3.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—atherosclerosis	3.25e-06	3.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SERPINE1—atherosclerosis	3.24e-06	3.38e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—atherosclerosis	3.21e-06	3.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—INS—atherosclerosis	3.19e-06	3.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—atherosclerosis	3.15e-06	3.29e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—INS—atherosclerosis	3.14e-06	3.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—atherosclerosis	3.14e-06	3.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—atherosclerosis	3.14e-06	3.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—atherosclerosis	3.09e-06	3.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—atherosclerosis	3.09e-06	3.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—atherosclerosis	3.09e-06	3.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARA—atherosclerosis	3.08e-06	3.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—atherosclerosis	3.01e-06	3.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AGT—atherosclerosis	2.98e-06	3.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—INS—atherosclerosis	2.98e-06	3.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—atherosclerosis	2.95e-06	3.09e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SERPINE1—atherosclerosis	2.93e-06	3.07e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—atherosclerosis	2.92e-06	3.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—atherosclerosis	2.92e-06	3.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—atherosclerosis	2.92e-06	3.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAV1—atherosclerosis	2.89e-06	3.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOA1—atherosclerosis	2.89e-06	3.02e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—atherosclerosis	2.88e-06	3.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—atherosclerosis	2.8e-06	2.93e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—atherosclerosis	2.76e-06	2.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—atherosclerosis	2.74e-06	2.87e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SERPINE1—atherosclerosis	2.74e-06	2.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—atherosclerosis	2.64e-06	2.76e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—atherosclerosis	2.61e-06	2.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—atherosclerosis	2.54e-06	2.66e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—atherosclerosis	2.52e-06	2.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—INS—atherosclerosis	2.5e-06	2.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—atherosclerosis	2.49e-06	2.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—atherosclerosis	2.48e-06	2.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKB1—atherosclerosis	2.45e-06	2.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK8—atherosclerosis	2.41e-06	2.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—atherosclerosis	2.38e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—atherosclerosis	2.33e-06	2.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—atherosclerosis	2.29e-06	2.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—atherosclerosis	2.25e-06	2.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—atherosclerosis	2.23e-06	2.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKB1—atherosclerosis	2.22e-06	2.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—atherosclerosis	2.2e-06	2.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—atherosclerosis	2.2e-06	2.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—atherosclerosis	2.2e-06	2.3e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—atherosclerosis	2.19e-06	2.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK8—atherosclerosis	2.19e-06	2.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—atherosclerosis	2.16e-06	2.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—atherosclerosis	2.11e-06	2.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—atherosclerosis	2.04e-06	2.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—atherosclerosis	2.03e-06	2.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—atherosclerosis	2.02e-06	2.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—atherosclerosis	2e-06	2.09e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—atherosclerosis	1.99e-06	2.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—atherosclerosis	1.91e-06	2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—atherosclerosis	1.86e-06	1.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—atherosclerosis	1.85e-06	1.94e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—atherosclerosis	1.81e-06	1.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—atherosclerosis	1.78e-06	1.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—atherosclerosis	1.73e-06	1.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—atherosclerosis	1.54e-06	1.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—atherosclerosis	1.42e-06	1.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—atherosclerosis	1.4e-06	1.46e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—atherosclerosis	1.3e-06	1.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—atherosclerosis	1.29e-06	1.35e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—atherosclerosis	1.27e-06	1.33e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—atherosclerosis	1.2e-06	1.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—atherosclerosis	1.01e-06	1.05e-05	CbGpPWpGaD
